An Opportunistic Pharma Pick
Premature disappointment over the prospect of Vanda's sole drug has left investors with a compelling opportunity says Morningstar Opportunistic Investor's Stephen Ellis.
Jeremy Glaser: An opportunistic pharma pick. I'm Jeremy Glaser with Morningstar.com. I am joined today by Stephen Ellis. He is an Equity Strategist here at Morningstar. He is going to pitch one of his best ideas in the pharmaceutical space right now.
Stephen, thanks for joining me.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.